相关实验视频
Updated: Jan 17, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
血糖水平和胰岛素的使用 每天和在住院期间,在住院的2型糖尿病患者中每天和在住院期间
Mikkel Thor Olsen1,2, Signe Hjejle Jensen2, Louise Mathorne Rasmussen2
1Steno Diabetes Center Copenhagen, Herlev 2730, Denmark.
Journal of the Endocrine Society
|September 22, 2025
概括
连续血糖监测 (CGM) 显著改善了2型糖尿病住院患者的范围 (TIR) 时间,与照顾点 (POC) 测试相比. 使用CGM导致更好的血糖控制和在住院期间减少胰岛素需求.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
- 医疗技术 医疗技术 医学技术
背景情况:
- 患有2型糖尿病的住院患者通常会经历血糖变化.
- 有效的葡萄糖监测对于优化胰岛素治疗和患者的治疗结果至关重要.
- 当前的监测方法可能无法完全捕捉不同医院轮班期间的血糖波动.
研究的目的:
- 为了比较持续血糖监测 (CGM) 与2型糖尿病住院患者的点诊 (POC) 血糖检测的有效性.
- 为了表征每日葡萄糖水平和胰岛素使用在不同的医院轮班.
- 为了告知治疗计划和改善在住院期间的血糖控制.
主要方法:
- 一个2中心随机试验的后期分析,涉及166名患有2型糖尿病的非ICU患者.
- 通过胰岛素定位算法指导的糖尿病管理中,CGM臂与POC臂的比较.
- 主要结局:住院期间的时间范围 (TIR) (3.9-10.0 mmol/L).
主要成果:
- 射程中的时间 (TIR) 在CGM手臂下放后改善到近90%,而在POC手臂 (P < .001) 中为60%.
- 两只手臂在白天班 (07:00-15:00) 中使用TIR最低,胰岛素使用最高.
- 与POC手臂相比,CGM手臂在所有班次中显示了明显较低的校正和食用胰岛素剂量.
结论:
- 持续血糖监测 (CGM) 在改善住院患者的血糖水平方面提供了持续的有效性.
- 与照顾点测试相比,CGM带来了优越的范围时间,即使降低了胰岛素剂量.
- 这些发现突显了CGM在加强住院患者的糖尿病管理方面的潜力.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Hypoglycemia and Glucagon
838
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
838
Insulin Formulations: Types and Delivery
659
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
659
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Hormones Regulating Blood Glucose
6.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.5K

